Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.
Age ≥ 18 years
Signed informed consent form and voluntary participation in this study
Histologically and/or cytologically confirmed diagnosis of cancer
Esophageal cancer
Pregnant or lactating women
Presence of contraindications to surgery
Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate
Presence of two or more concurrent primary tumors
Parallel
Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients
DrugValidation of intervention efficacy through enhanced intervention in nutritionally high-risk patients
Standard nutritional intervention was administered as a positive control to validate experimental efficacy.
DrugStandard nutritional intervention was administered as a positive control to validate experimental efficacy.
Administration of placebo as a negative control to validate experimental efficacy
Other interventionAdministration of placebo as a negative control to validate experimental efficacy
Change in skeletal muscle index (SMI, cm²/m²)
Skeletal muscle index (SMI) is calculated from cross-sectional CT images at the third lumbar vertebra (L3) level and normalized by height (cm²/m²).
Change in serum albumin (g/L)
Serum albumin level measured using standard laboratory methods.
Change in C-reactive protein (CRP, mg/L)
CRP levels measured as a marker of systemic inflammation.
Change in handgrip strength (kg)
Handgrip strength measured using a calibrated dynamometer.
Change in gait speed (m/s)
Gait speed assessed using a standardized walking test.
Click on the lead sponsor to view all of their trials.
